Sustainable Ionizable Lipids for Next-Generation mRNA Medicines
Enabling scalable, locally sourced solutions for vaccines and RNA therapeutics in emerging markets
Who we Are
Green Lipids is a biotechnology venture that is developing novel ionizable lipids derived from cashew nutshell liquid (CNSL) for use in lipid nanoparticles (LNPs).
Our mission is to enable cost-effective, scalable, and a regionally accessible lipid supply for mRNA vaccines, nucleic acid therapeutics and transfection reagents. The aim is to support global health equity and pandemic preparedness.
Lipid nanoparticle components are critical for global deployment of mRNA technologies.
Current ionizable lipid supply chains for low- and middle-income countries:
are costly
have a limited supplier base
are vulnerable to disruption
Green Lipids addresses these drawbacks by enabling alternative, scalable, and locally adaptable ionizable lipid production.
Sustainable Feedstock
We utilise CNSL, a renewable by-product of the cashew nut industry, to develop ionizable lipids that reduce dependence on petrochemical-derived feedstocks.
mRNA Delivery Performance
Our ionizable lipid platform is designed to support efficient delivery of nucleic acids across a range of applications, including vaccines, transfections and gene-based medicines.
Local Manufacturing Enablement
We align with global health initiatives, including regional mRNA production in Africa and other low- and middle-income countries.
HISTORY
Green Lipids builds on research developed within the University of the Witwatersrand (Wits) at the School of Chemistry and theWits/SAMRC Antiviral Gene Therapy Research Unit (AGTRU). Green Lipids is also aligned with the broader WHO- and Medicines Patent Pool (MPP)-supported mRNA technology transfer platform. Scale-up synthesis is being supported by the European Union and German Federal government through the German Agency for International Cooperation (GIZ).